Need for a paradigm shift in cancer prevention and clinical oncology

Expert Review of Anticancer Therapy

Volumn 7, Issue 10, 2007, Pages 1363-1367

  Ebert, Matthias P ^a   Schmid, Roland ^a   Röcken, Christoph ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biomarker; Cancer; Diagnosis; Oncology; Prevention; Screening

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PROTON PUMP INHIBITOR; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; ANGIOPLASTY; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER THERAPY; CHRONIC GASTRITIS; DIET THERAPY; DIGESTIVE SYSTEM CANCER; EUROPEAN UNION; GASTROESOPHAGEAL REFLUX; HEART INFARCTION; HELICOBACTER INFECTION; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATOGASTROINTESTINAL CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROGNOSIS; RISK ASSESSMENT; SCHISTOSOMIASIS; ULCERATIVE COLITIS; VERRUCA VULGARIS; DISEASE COURSE; DISEASE MANAGEMENT; EUROPE; FORECASTING; NEOPLASM; ONCOLOGY; REVIEW;

DISEASE MANAGEMENT; DISEASE PROGRESSION; EUROPE; FORECASTING; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PROGNOSIS; RISK ASSESSMENT;

EID: 35848947520     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.10.1363     Document Type: Article

References (10)

1. Jemal A, Murray T, Ward E et al. Cancer Statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Boige V, Malka D, Ducreux M. Therapeutic strategies using VEGF inhibitors in colorectal cancer. Bull. Cancer 92, S29-S36 (2005).
3. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6, 753-763 (2006).
4. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 56, 69-83 (2006).
5. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J Clin. 57, 43-66 (2007).
6. Heart Protection Study Collaborative; Mihaylova B, Briggs A, Armitage J et al. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. Br. Med. J. 333, 1145 (2006).
7. Pignone M, Earnshaw S, Tice JA et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann. Intern. Med. 144, 326-336 (2006).
8. Gaspardone A, Versaci F. Coronary stenting and inflammation. Am. J. Cardiol. 96, 65L-70L (2005).
9. Mulcahy HE, O'Donoghue DP. Duration of colorectal cancerCEA symptoms and survival: the effect of confounding clinical and pathological variables. Eur. J. Cancer 33, 1461-1467 (1997).
10. Kelloff GJ, Lippman SM, Dannenberg AJ et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin. Cancer Res. 12, 3661-3697 (2006).